SCHEMBL20857053

SCHEMBL20857053

C=CC(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(Oc2ccccc2)c(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2A1 Q16548 6/20 0.43
STK39 Q9UEW8 1/20 0.40
NR1H3 Q13133 10/20 0.38
NR1H2 P55055 9/20 0.38
RXRA P19793 2/20 0.38
MEN1 O00255 1/20 0.37
NR1I2 O75469 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
VHL P40337 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20857061 0.89 STK39 (0.41) STK39NR1H3NR1H2RXRAMEN1
SCHEMBL29883277 0.78 GSTO1 (0.48) MAPT
SCHEMBL18763021 0.78 GSTO1 (0.48) MAPT
SCHEMBL23256711 0.74 STAT3 (0.36) CYP1A2CYP3A4CYP2D6CYP2C9SLC6A2
SCHEMBL20857040 0.70 RNF4 (0.48) STK39ALDH1A1MAPT
SCHEMBL22387504 0.70 STK39 (0.48) STK39NR1H3NR1H2MEN1ALDH1A1
SCHEMBL6728076 0.66 CYP3A4 (0.49) MAPTCYP3A4
SCHEMBL21168598 0.65 CYP3A4 (0.46) MAPTCYP3A4
SCHEMBL20857071 0.65 RNF4 (0.41) MEN1ALDH1A1KMT2A
SCHEMBL22371835 0.64 NPC1 (0.44) MEN1ALDH1A1MAPTKMT2ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021076703-A1 COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS VIVIDION THERAPEUTICS, INC. (US) 2021-04-22 WO disclosed
US-20200278355-A1 CONJUGATED PROTEINS AND USES THEREOF SCRIPPS RESEARCH INST (US) 2020-09-03 US disclosed
US-20200278355-A1 CONJUGATED PROTEINS AND USES THEREOF SCRIPPS RESEARCH INST (US) 2020-09-03 US disclosed
EP-3688472-A1 CONJUGATED PROTEINS AND USES THEREOF The Scripps Research Institute (US) 2020-08-05 EP disclosed
WO-2019067741-A1 CONJUGATED PROTEINS AND USES THEREOF THE SCRIPPS RESEARCH INSTITUTE (US) 2019-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200278355-A1 CONJUGATED PROTEINS AND USES THEREOF KEAP1, GSTK1, GSTM2 BCL2A1 1536/4885STK39 3463/4885NR1H3 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.